- Home
- SLSR vs FTRE Comparison
SLSR vs FTRE Comparison
Compare SLSR & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSR
- FTRE
- Stock Information
- Founded
- SLSR 2018
- FTRE 1996
- Country
- SLSR Switzerland
- FTRE United States
- Employees
- SLSR N/A
- FTRE N/A
- Industry
- SLSR
- FTRE Medical Specialities
- Sector
- SLSR
- FTRE Health Care
- Exchange
- SLSR NYSE
- FTRE Nasdaq
- Market Cap
- SLSR 539.0M
- FTRE 483.5M
- IPO Year
- SLSR N/A
- FTRE N/A
- Fundamental
- Price
- SLSR $3.61
- FTRE $5.50
- Analyst Decision
- SLSR Buy
- FTRE Hold
- Analyst Count
- SLSR 2
- FTRE 11
- Target Price
- SLSR $10.00
- FTRE $18.00
- AVG Volume (30 Days)
- SLSR 82.4K
- FTRE 2.7M
- Earning Date
- SLSR 05-08-2025
- FTRE 05-12-2025
- Dividend Yield
- SLSR N/A
- FTRE N/A
- EPS Growth
- SLSR N/A
- FTRE N/A
- EPS
- SLSR N/A
- FTRE N/A
- Revenue
- SLSR N/A
- FTRE $2,696,400,000.00
- Revenue This Year
- SLSR N/A
- FTRE N/A
- Revenue Next Year
- SLSR N/A
- FTRE $3.38
- P/E Ratio
- SLSR N/A
- FTRE N/A
- Revenue Growth
- SLSR N/A
- FTRE N/A
- 52 Week Low
- SLSR $2.50
- FTRE $4.77
- 52 Week High
- SLSR $3.76
- FTRE $38.04
- Technical
- Relative Strength Index (RSI)
- SLSR 58.85
- FTRE 32.44
- Support Level
- SLSR $3.32
- FTRE $4.82
- Resistance Level
- SLSR $3.58
- FTRE $5.31
- Average True Range (ATR)
- SLSR 0.28
- FTRE 0.64
- MACD
- SLSR 0.07
- FTRE 0.14
- Stochastic Oscillator
- SLSR 97.87
- FTRE 26.45
About SLSR SOLARIS RESOURCES INC
Solaris Resources Inc is advancing a portfolio of copper and gold assets in the Americas, which includes a high-grade resource with expansion and additional discovery potential at the Warintza copper and gold project in Ecuador; discovery potential on the grass-roots Tamarugo project in Chile and Capricho and Paco Orco projects in Peru, and the La Verde joint venture project.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.